Related references
Note: Only part of the references are listed.Phosphorylation of the C-Raf N Region Promotes Raf Dimerization
Maho Takahashi et al.
MOLECULAR AND CELLULAR BIOLOGY (2017)
CRAF gene fusions in pediatric low-grade gliomas define a distinct drug response based on dimerization profiles
P. Jain et al.
ONCOGENE (2017)
Mechanisms of Acquired Resistance to BRAF V600E Inhibition in Colon Cancers Converge on RAF Dimerization and Are Sensitive to Its Inhibition
Rona Yaeger et al.
CANCER RESEARCH (2017)
New perspectives for targeting RAF kinase in human cancer
Zoi Karoulia et al.
NATURE REVIEWS CANCER (2017)
An Integrated Model of RAF Inhibitor Action Predicts Inhibitor Activity against Oncogenic BRAF Signaling
Zoi Karoulia et al.
CANCER CELL (2016)
Preclinical efficacy of a RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF-mutant lung cancer
Ross A. Okimoto et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2016)
Inhibition of RAF lsoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers
Sheng-Bin Peng et al.
CANCER CELL (2015)
BRAF Mutants Evade ERK-Dependent Feedback by Different Mechanisms that Determine Their Sensitivity to Pharmacologic Inhibition
Zhan Yao et al.
CANCER CELL (2015)
Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT) A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology
Donavan T. Cheng et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2015)
RAF inhibitors that evade paradoxical MAPK pathway activation
Chao Zhang et al.
NATURE (2015)
Inhibition of mutant BRAF splice variant signaling by next- generation, selective RAF inhibitors
Kevin J. Basile et al.
PIGMENT CELL & MELANOMA RESEARCH (2014)
Antitumor Activity of the Selective Pan-RAF Inhibitor TAK-632 in BRAF Inhibitor-Resistant Melanoma
Akito Nakamura et al.
CANCER RESEARCH (2013)
Paradoxical activation and RAF inhibitor resistance of BRAF protein kinase fusions characterizing pediatric astrocytomas
Angela J. Sievert et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
Poulikos I. Poulikakos et al.
NATURE (2011)
RG7204 (PLX4032), a Selective BRAFV600E Inhibitor, Displays Potent Antitumor Activity in Preclinical Melanoma Models
Hong Yang et al.
CANCER RESEARCH (2010)
Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF
Sonja J. Heidorn et al.
CELL (2010)
RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF
Poulikos I. Poulikakos et al.
NATURE (2010)
Melanomas acquire resistance toB-RAF(V600E) inhibition by RTK or N-RAS upregulation
Ramin Nazarian et al.
NATURE (2010)
Positive and negative regulation of Raf kinase activity and function by phosphorylation
H Chong et al.
EMBO JOURNAL (2001)
Share Paper
